Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
- Jung, Eun Suk; Kim, Ji Hoon; Yoon, Eileen L.; Lee, Hyun Jung; Lee, Soon Jae; Suh, Sang Jun; Lee, Beom Jae; Seo, Yeon Seok; Yim, Hyung Joon; Seo, Tae-Seok; Lee, Chang Hee; Yeon, Jong Eun; Park, Jong-Jae; Kim, Jae Seon; Bak, Young Tae; Byun, Kwan Soo
- Issue Date
- Elsevier BV
- Hepatocellular carcinoma; Response; Survival; Transarterial chemoembolization
- Journal of Hepatology, v.58, no.6, pp.1181 - 1187
- Journal Title
- Journal of Hepatology
- Start Page
- End Page
- Background & Aims
Recently, new methods, including the concept of viable enhancing tumor such as EASL and mRECIST, have been proposed for substitution of the conventional WHO and RECIST criteria in hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). Herein, we evaluated the differences of four methods and compared the association of these methods with the prognosis of HCC patients undergoing TACE.
We retrospectively reviewed 114 consecutive newly diagnosed HCC patients who underwent TACE as initial treatment. We evaluated the intermethod agreement (κ values) between the methods and compared their association with the prognosis of HCC patients.
The κ values for EASL vs. WHO, EASL vs. RECIST, mRECIST vs. WHO, and mRECIST vs. RECIST were low, of 0.102, 0.088, 0.112, and 0.122, respectively. However, good correlations were observed for WHO vs. RECIST and EASL vs. mRECIST (κ = 0.883, κ = 0.759, respectively p <0.001). The median OS was 32.3 months. Hazard ratios (HR) for survival in responders compared with non-responders were 0.21 (95% CI; 0.12–0.37, p <0.001) for EASL and 0.27 (95% CI; 0.15–0.48, p <0.001) for mRECIST. The mean survival of responders was significantly longer than that of non-responders in both EASL (40.8 vs. 16.9 months, p <0.001) and mRECIST (41.1 vs. 20.7 months, p <0.001). In multivariate analysis, EASL response (HR 0.21, 95% CI 0.11–0.40, p <0.001) and mRECIST response (HR; 0.31, 95% CI, 0.17–0.59, p <0.001) were independently associated with survival.
The response assessment by EASL and mRECIST could reliably predict the survival of HCC patients undergoing TACE and could be applicable in practice in preference to the conventional WHO and RECIST criteria.
- Files in This Item
- There are no files associated with this item.
- Appears in
- 2. Clinical Science > Department of Radiology > 1. Journal Articles
- 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.